LATEST NEWS

 

Treating Patients Through the Lens of a View-Master

2021 ACOFP Diversity, Equity and Inclusion Award Recipient Tejal R. Patel, DO, shares her story as an Asian-American osteopathic family physician, comparing individual circumstances to looking through a View-Master. Learn how this shift in perspective can help you in treating your patients and working with each other by reading the recent blog, Treating Patients Through the Lens of a View-Master.

We Want to Know: Why Did You Choose Osteopathic Medicine?

Each year, the osteopathic medical profession joins together to raise awareness of osteopathic medicine and the distinctive care DOs provide. Next week (April 18–24) is National Osteopathic Medicine Week, and we want to know: Why did you choose osteopathic medicine? Share your answer in this short survey, and you may be featured in next week's newsletter, on the ACOFP blog or in social media.

Rapid Development and Deployment of Respiratory Evaluation Clinics in Response to the COVID-19

As COVID-19 exploded as a global pandemic in early 2020, emergency departments (ED) became overwhelmed, and the shift to telemedicine began. However, for those individuals who were too ill to do a virtual visit but not ill enough to be seen in the ED, physicians needed to find an alternative. Read the recent Osteopathic Family Physician (OFP) article, Rapid Development and Deployment of Respiratory Evaluation Clinics in Response to the COVID-19, to learn how one department developed a Respiratory Evaluation Clinic with two locations to perform necessary testing on patients, while keeping them and staff as safe as possible. Then, complete the March/April 2021 OFP CME quiz—free for ACOFP members.

CDC and FDA Recommend Pause in Use of Johnson & Johnson Vaccine

According to the joint statement released April 13 by the U.S. Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA), the agencies are currently reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the Johnson & Johnson (Janssen) vaccine. While more than 6.8 million doses of the J&J vaccine have been administered as of April 12 and these adverse events appear to be extremely rare, the CDC and FDA recommend a pause in the use of this vaccine out of an abundance of caution. Healthcare providers are asked to report adverse events in patients who have already received the vaccine to the Vaccine Adverse Event Reporting System.